Focus: Immunovant is a public biotechnology company headquartered in Durham, NC, focused on monoclonal antibody therapeutics for neurology, immunology, and endocrinology indications. The company is in active development stage with a diversified pipeline across multiple autoimmune and neurological diseases.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
A scientifically interesting but capital-dependent mid-stage biotech with meaningful pipeline depth—best for candidates seeking early-stage exposure in immunology with tolerance for clinical/financial risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Immunovant
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Immunovant's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo